| Date | Title | Description |
| 17.07.2026 | Notice of annual general meeting in EQL Pharma AB | Notice of annual general meeting in EQL Pharma AB
Fri, Jul 17, 2026 10:15 CET Report this content
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 20 August 202... |
| 10.07.2026 | ChrysCapital’s open offer for Novartis India fails as shares surge | The Novartis logo at a building in Rotkreuz, Switzerland | Credit: Reuters/Arnd Wiegmann
Homegrown private equity firm ChrysCapital’s open offer to acquire additional shares of Novartis India Ltd has found no takers as the drugmaker’s share... |
| 18.05.2026 | Kotak Alts' life sciences fund backs gene therapy firm | Credit: 123RF.com
Kotak Alternate Asset Managers Ltd has invested in Cellogen Therapeutics, a biotechnology firm focussed on cell and gene therapies.
Kotak Alts has invested Rs 20 crore ($2 million) in the biotech firm through its early- to... |
| 20.02.2026 | ChrysCapital inks $159 mn control deal for Novartis India, makes open offer | The Novartis logo at a building in Rotkreuz, Switzerland | Credit: Reuters/Arnd Wiegmann
Homegrown private equity firm ChrysCapital has agreed to acquire Swiss pharmaceutical major Novartis AG’s entire stake in its Mumbai-listed unit for Rs... |
| 20.10.2025 | Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions | LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries.
This strategic move... |
| 11.08.2025 | Intas & Accord signs Agreement to acquire Prothya Biosolutions | AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leadin... |
| 01.03.2025 | Motilal Oswal's Bold Bet on Megafine Pharma: A Strategic Move in the API Landscape | In a significant move that underscores the shifting dynamics of the pharmaceutical industry, Motilal Oswal Alternates (MO Alts) has acquired a majority stake in Megafine Pharma Pvt Ltd for ₹460 crore. This investment marks MO Alts' first ma... |
| 25.02.2025 | MO Alts picks up majority stake in API maker Megafine Pharma | Credit: Thinkstock
Motilal Oswal Alternates (MO Alts), the private equity arm of Motilal Oswal Financial Services Ltd, has invested Rs 460 crore to acquire a majority stake in active pharmaceutical ingredient (API) manufacturing firm Megafi... |
| 13.02.2025 | The New Frontier of Competition: India’s Regulatory Landscape for Private Equity | The world of private equity is changing. No longer can investors wade through deals without a care. The Competition Commission of India (CCI) is on high alert. Its focus? Common ownership in rival firms. This shift reflects a global trend. ... |
| 12.02.2025 | What the CCI's concerns over common ownership mean for private equity deals | Anisha Chand (left) and Yatharth V. Singh, Khaitan & Co
Gone are the days when private equity investments were considered entirely benign from an antitrust perspective. Over the last five years, the Competition Commission of India (CCI)... |
| 07.02.2025 | Henlius and Dr. Reddy's Partnership: A New Dawn for Biosimilars in Oncology | In the fast-paced world of biopharmaceuticals, partnerships can be the lifeblood of innovation. Recently, Shanghai Henlius Biotech, Inc. and Dr. Reddy's Laboratories forged a significant alliance that could reshape the landscape of oncology... |
| 05.02.2025 | Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC
Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC
Serplulimab h... |
| 23.01.2025 | Kotak Alternate Asset hits first close of third life sciences-focused PE fund | Credit: 123RF.com
Kotak Alternate Asset Managers Ltd, the alternative asset management arm of Kotak Mahindra Group, said Thursday it has marked the first close of its third healthcare and life sciences-focused private equity fund.
The firm ... |
| 25.12.2024 | More of the world’s medicines could get made in India, if it can cure its pharma ills | Listen
11 min
New: You can now listen to articles.
This audio is generated by an AI tool.
MUMBAI: Amid a rash of drug-related recalls and deaths, India’s pharmaceutical sector is racing to improve its quality and safety standards as it eyes... |
| 03.12.2024 | Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. | - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs wit... |
| 21.09.2024 | The Future of Healthcare: Innovation and Collaboration at Pharmavision India 2024 | The healthcare landscape is shifting. At the forefront of this change is the 15th annual Pharmavision India conference, set to take place on September 25-26, 2024, in Ahmedabad and Hyderabad. This event is not just a gathering; it’s a cruci... |
| 21.09.2024 | Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC -
HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatmen... |
| 18.09.2024 | Clarivate Announces 15th Annual Pharmavision India Conference Agenda | Industry leaders to discuss AI in healthcare, cell and gene therapy, market access and more at premier life sciences event
LONDON, Sept. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intellig... |
| 03.05.2024 | Delhi HC directs action against use of oxytocin in dairy colonies | - |
| 29.04.2024 | Henlius Trastuzumab Receives FDA Approval in the United States | SHANGHAI, April 29, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas Pharmaceuticals, Ltd.), has received approval from ... |
| 21.03.2024 | Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved | SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit of... |
| 22.07.2021 | Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab) | Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement
AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continue... |
| 04.03.2021 | Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States | TAIPEI, March 4, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals ("Intas") for the US commercializati... |
| 12.05.2012 | ChrysCapital Invests $56.2M In Intas Pharmaceuticals | Private equity major ChrysCapital is investing Rs 300 crore ($56.2 million) in Ahmedabad-based Intas Pharmaceuticals Ltd, increasing its existing stake of 11.2 per cent in the fast-growing pharma company. With this investment in place, Inta... |
